


Utilising Artificial Intelligence (AI) in the Diagnosis of Psychiatric Disorders: A Narrative Review

MANSI KHARE¹, SOURYA ACHARYA², SAMARTH SHUKLA³, HARSHITA⁴, ANKITA SACHDEV⁵

ABSTRACT

In the era of machinery, Artificial Intelligence (AI) has become the new tool for managing patients in psychiatry. Nowadays, many psychiatric disorders are being diagnosed and treated with the help of AI. New technologies like Machine Learning (ML), robots, Deep Learning (DL), and sensor-based systems provide a different perspective on psychiatric disorders. The present narrative review article summarised the use of AI in diagnosing and treating psychiatric disorders. AI can assist a patients with a psychiatric diseases in prognosis, clinical diagnosis, management therapy, and addressing clinical and technological issues. It highlights various AI methods used in mental healthcare, with a focus on multiple ML perspectives. Additionally, AI has the potential to address several factors, including privacy, transparency, bias, and other social and ethical considerations. The aim of the present review was to redefine mental disorders more objectively, personalise treatments, facilitate early diagnosis, and provide patients with more choices in their care. Through the present article, author aimed to highlight the use of AI in the diagnosis of various psychiatric disorders such as depression, schizophrenia, bipolar disorder, Autism Spectrum Disorder (ASD), and Alzheimer's Disease (AD).

Keywords: Bipolar, Mental, Neuroimaging, Robotics, Schizophrenia

INTRODUCTION

The AI refers to the emulation of human intelligence in machines, which are designed to think like people and replicate their actions [1]. AI techniques focus on actively manipulating the environment, making consensus-based decisions, utilising robotics, and employing collective intelligence techniques. AI can be categorised into several types based on the level of its system's functionality: AI with self-awareness, limited memory, theory of mind, and reactive machines [1]. The following procedures and techniques can be employed in conjunction with AI to address practical issues: (DL), robotics, expert systems, fuzzy logic, natural language processing, and (ML) [1]. Mental disorders have an impact on psychological, social, behavioural, and emotional well-being [1]. The variability in the presentation of diseases, signs, and symptoms, coupled with the limitations in the understanding of aetiological pathways, makes diagnosing mental disorders challenging. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the International Classification of Diseases (ICD-11) manuals serve as the foundation for current methods of diagnosing mental illnesses [1]. The process of diagnosing mental problems using diagnostic instruments, interviewing family members or caregivers, and gathering health histories can be time consuming and resource intensive [2].


For supporting and enhancing the diagnostic and interventional aspects of psychiatric treatment, digital health tools and technology present excellent practices [3]. Mental diseases have been diagnosed using AI. The AI is a significant and popular example of these digital technologies because it enables machines to identify complex, underlying patterns and provide practical insights by understanding queries and sifting through and connecting vast amounts of data [4]. AI can significantly transform how to perceive, diagnose, and treat mental illnesses. AI can be utilised with electronic records, radiological investigations, sensor-based tracking systems, and social media to predict and categorise psychiatric disorders and issues such as suicidality [5]. An increasing range of AI applications to electronic records, investigations, sensor-based tracking systems, and social media have successfully predicted and categorised mental issues like

suicidality in various domains [4]. By focusing on various illustrative publications, it provides insights into AI techniques in mental health care, aiming to assist with diagnosis, prognosis, management, and addressing clinical and technological issues [2-4,6]. It sheds light on how the use of AI has transformed the landscape of diagnosing and treating psychiatric disorders. The advantages of using AI in psychiatry may not be immediately apparent. One concern is that individuals may be hesitant to share their personal issues and history with doctors [2]. Through AI, it would be easier for patients to communicate their problems to a doctor without worrying about being judged. Machines can provide more effective treatment because they lack human factors such as distraction, stress, and fatigue [3]. They are also immune to the same personal biases that can affect human therapists. AI robots can take into account a patient's race, ethnicity, or socioeconomic background when adjusting treatment. However, AI algorithms may have drawbacks such as bias, fragility, and limited applicability outside their training domain [1].

These limitations are particularly pronounced in cases of mental health problems because these conditions require softer skills such as building rapport with patients, establishing relationships, and observing emotions and behaviour [4]. Another drawback is the lack of human empathy and compassion, which are essential elements in treating patients who have experienced mental trauma or are dealing with a mental condition. AI devices must undergo the same rigorous regulatory review and risk assessment procedures as conventional medical devices before they can be approved for clinical use [5]. When using AI applications, Diagnostic and Statistical Manual of Mental Disorders (DSMs) criteria guidelines must be followed for research or clinical evidence purposes. There is a remote possibility that human-machine interactions may not translate to human-human interactions or may even further restrict human-to-human interactions [3,4]. The goal of AI is to assist people by acting as their assistants in improving the world. Their makeup should include prosocial traits such as empathy, generosity, self-awareness, and effective control, as well as the ability to accept and decisively act on differing points of view [1,3].

Artificial Intelligence (AI) in Depression

Major Depressive Disorder (MDD) is a highly prevalent psychiatric disorder that has a significant impact on socioeconomic burden and Quality of Life (QoL). The criteria outlined in the DSM and a patient's response to treatment are commonly used for diagnosing MDD [5]. In the case of depression, (ML) techniques can generate reliable predictions of treatment outcomes [6]. ML encompasses a range of models that utilise empirical data to create training models and accurately classify new input [7]. Its benefits for MDD extend beyond diagnosis and include the ability to predict the future progression of the disease. Its capacity for individual-level analysis is particularly noteworthy in recent years. Research focused on depression biomarkers has seen substantial growth, particularly in using MRI in conjunction with pattern recognition methods [8,9]. These techniques can predict treatment outcomes and differentiate between individuals with depression and healthy controls with high accuracy [10,11]. Exploratory research is still predominantly focused on strategies for integrating MRI data with ML techniques. The merging of ML algorithms and MRI data in depression is gaining increasing attention due to its high potential and ability to reveal additional information about underlying brain regions. Studies have utilised genetic, Electronic Medical Record (EMR), neuroimaging, and speech data to model the progression of depression [12]. Patients at risk of self-harm behaviour can be identified using demographic, social, mental, and physical health data, as well as administrative data from healthcare encounters. A history of high-risk events can predict short-term future high-lethality suicide attempts. Multimodal sensing, which includes wearables, smartphones, physiological sensors such as heart rate and electrodermal activity, as well as ambient sensors like motion, temperature, and light, enables the continuous collection of real-world data on symptoms, treatment response, behaviours, thoughts, and emotions [13,14]. If it becomes possible to continuously identify behaviours related to mental health, a new generation of highly personalised, contextualised, dynamic mobile health (mHealth) tools that can listen rather than ask and seamlessly interact, learn, and grow with users could emerge [14]. Platforms such as mindLAMP [15], AWARE [16], and crosscheck [17] facilitate multimodal data collection, making continuous remote monitoring and the detection of subjective and objective signs of psychotic relapse more accessible. The urgency of reversing the trend of increasing suicide rates has led to the development of technology-based tools, such as text messaging, smartphone apps, smartphone sensors, electronic health records, and ML algorithms, which can provide crucial data to improve suicide prognosis or offer immediate support to those at risk [16]. Innovative data processing, modelling, and signal detection techniques are being developed and evaluated to detect changes within individuals over time, with the aim of enhancing treatment and prevention [17,18]. This would expedite the identification of individuals at risk or in need of treatment. Additionally, a number of chatbots and applications [Table/Fig-1] [1,2]. It plays a significant role in the treatment of depression, not only providing emotional support but also addressing underlying conditions [19,20].



[Table/Fig-1]: Different form of Artificial Intelligence (AI) use in psychiatric disorders [1,2].

Artificial Intelligence (AI) in Schizophrenia

Schizophrenia is a highly diverse psychiatric disorder characterised by abnormal perceptions of reality. AI has the potential to be applied in various ways to address this heterogeneity and improve predictions and understanding of the disorder's neurological basis. New developments in functional mapping and electric field modeling can enhance the effectiveness of brain stimulation on social cognitive networks [21]. Targeting specific networks using techniques like repetitive Transcranial Magnetic Stimulation (rTMS) can be utilised. New strategies are being developed to consider neuroanatomical diversity and optimise coil placement to maximise target engagement for each individual [21]. By combining L1-norm authorised sparse canonical correlation analysis and Sparse Logistic Regression (SLR), reliable classification of Schizophrenia Spectrum Disorder (SSD) has been achieved in rs-fMRI studies [21]. The spectrum of schizophrenic disorders includes schizophrenia, schizotypal personality disorder, schizophreniform disorder, brief psychotic disorder, schizoaffective disorder, delusional disorder, and psychosis induced by substance use or medical conditions [22]. The European First Episode Schizophrenia Trial (EUFEST) trial, a large multisite treatment database in Europe for first-episode schizophrenia, has provided prospective phenotypic data on mental disorders, enabling accurate prediction of treatment outcomes using effective ML techniques [23]. Recent AI techniques have demonstrated that Functional Striatal Abnormalities (FSA) are strongly associated with a range of severity in the spectrum of mental disorders, with the most pronounced dysfunction observed in schizophrenia [24].

Artificial Intelligence (AI) in Bipolar Disorder

The ML approaches can provide physicians and researchers with crucial information for the diagnosis, personalised therapy, and prognostic guidance for patients with bipolar disorder due to the clinical heterogeneity of samples. By utilising multivariate techniques and ML, available data can be considered simultaneously. Furthermore, ML-generated outcome biomarkers can help determine the type and level of care required by the patient immediately. Supervised ML, based on neuroimaging data from previous responders and non responders, may be able to predict the success of a therapy and aid in selecting the best course of action [25]. In high-risk cases, ML could assist in predicting the transition to full-blown bipolar disorder [26]. Identifying those at greatest risk of bipolar disorder would enable the application of targeted preventive interventions. AI focuses on genetic data, cognitive or clinical measures, peripheral biomarkers, electrophysiological techniques, and multimodal strategies for diagnosing bipolar disorder. Various markers and ML algorithms achieve accurate categorisation of bipolar disorder. With the help of ML, bipolar disorder can be accurately distinguished from other mental illnesses. However, further research is needed to establish the best practices in this approach [25-27].

Artificial Intelligence (AI) in Autism Spectrum Disease

The results of rs-fMRI studies have demonstrated a valid neuroimaging-based classifier for Autism Spectrum Disorder (ASD) that shows the spatial distribution of the 16 Fragment Crystallisable (FCs) found in the data at various locations, as agreed upon by machine learning algorithms. Additionally, genome-level investigations have revealed a significant level of polygenic risk for ASD in relation to schizophrenia, but not in relation to Attention Deficit Hyperactivity Disorder (ADHD) or Major Depressive Disorder (MDD) [26-28]. Clinical and behavioural investigations provide growing evidence of a connection between ASD and schizophrenia [28]. AI has been extensively utilised to explore ASD, with the ultimate goal of streamlining and expediting the diagnostic process and enabling early access to therapy [28]. ML shows potential in various ASD investigations, including behaviour, locomotion, speech, facial emotion expression, neuroimaging, genetics, and metabolomics [29,30]. Consequently, AI techniques are increasingly being utilised and accepted, demonstrating the effectiveness of ML methods in

extracting information from large datasets. This makes ML an attractive tool for ongoing ASD clinical and research projects, offering potential avenues for enhancing ASD screening, diagnosis, and treatment tools. Cutting-edge technologies like ML have been studied and applied to increase diagnostic efficiency, speed, and quality in ASD research. These ML methods include artificial neural networks, support vector machines, a priori algorithms, and decision trees [31]. Many of these methods have been used to construct prediction models for autism-related datasets. In the rehabilitation of autistic patients, robots are being employed as social interaction facilitators. Robot-assisted Autism Therapy (RAAT) is used to encourage children to speak or engage in activities [27,30]. The robot can interact with autistic children in ways that promote the development of shared attention. Video games are also utilised to enhance motor skills and body schema orientation [26,30].

Artificial Intelligence (AI) in Alzheimer's Disease

Breakthroughs in high-quality omics platforms and imaging technologies present unprecedented opportunities to explore the origin and evolution of diseases. ML approaches offer new ways to handle multiscale data, integrate data from various sources, explain etiological and clinical heterogeneity, and discover new biomarkers. In Alzheimer's research, AI is applied in molecular neuroimaging, particularly in Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) [32]. Optical Coherence Tomography (OCT) is a scalable imaging technique used for extensive data in neurology, particularly in neurodegenerative diseases [32]. A transcriptomic-based approach to drug repurposing involves contrasting medication-induced gene expression with AD gene expression. AI has also shown benefits in social and companionship roles, as simple animal-like robots have been found to reduce loneliness ratings in older individuals [32,33]. Socially Assistive Robots (SAR) have been shown to increase social contact with peers of the subject [34]. Robot-assisted therapy is also utilised in the treatment of Alzheimer's. Combining computer capacity with quantifiable chemical patterns, such as using ML and AI technologies, can help address these challenges. Wearable AI devices and gadgets are also used in the rehabilitation of Alzheimer's patients. Several applications and chatbots provide emotional, social, and mental support for individuals with cognitive impairment [33,34]. In addition to biofluid biomarkers, other modalities such as electrical signal measurements of brain waves, AI-mediated memory tests, and online language analysis are being investigated for AD diagnosis using AI-mediated data analysis techniques [35]. ML and AI have the potential to open new avenues for precise, non invasive, and accessible early diagnosis of AD, as well as personalised techniques for disease management based on specific prognoses and therapy responses. AI classifiers can assist in identifying individuals at high risk of developing psychotic illnesses using neuroimaging data or cognitive testing [36]. AI can significantly accelerate, improve accuracy, and enhance the objectivity of neurodegenerative disease diagnosis [36].

Artificial Intelligence (AI) in Attention Deficit Hyperactivity Disorder (ADHD)

The heterogeneous disorder known as ADHD affects the neurodevelopment of the brain. Diagnostic tools for ADHD include motion analysis, physiological signals, questionnaires, gaming simulators, performance tests, and brain MRI [37]. However, there has been a neglect of other evaluation techniques for ADHD apart from MRI and a lack of focus on utilising data from wearable devices such as Photoplethysmography (PPG), Electrocardiography (ECG), and motion data for diagnosing ADHD [38]. Personalised educational aids have the potential to improve learning outcomes, facilitate better social integration, and reduce stigma, social exclusion, and stressful situations like bullying, which are common factors contributing to suicide attempts [39]. A

significant advantage of ML approaches is their ability to consider inter-regional correlations in the brain, enabling the identification of subtle and geographically dispersed effects [40]. ML models enable individual level statistical inference, which can aid in making individual diagnostic or prognostic judgments. In addressing the limitations of various mental disorders, ML and DL methods have been applied to diagnose ADHD. They have been utilised in cognitive behaviour therapy, training, rehabilitation, behavioural change, psychosocial motivation, attention improvement, and feedback [41].

Artificial Intelligence (AI) in Post-traumatic Stress Disorder (PTSD)

The PTSD reactions are characterised by variability in their clinical manifestations and aetiologies. ML technologies are being employed in medical disciplines that face similar challenges of heterogeneity in aetiology and outcome to address this fundamental variability [42]. The identification of PTSD in patients can be done using imaging data, biometric data {such as sleep, Heart Rate Variability (HRV), and skin conductance}, and computer or smartphone questionnaires collected through linked devices [43]. Combining MRI and ML techniques makes it feasible to identify a patient with PTSD. Monitoring techniques have been utilised to assess the diagnostic criteria for PTSD, with Ecological Momentary Assessment (EMA) emerging as the most promising method [43,44]. Analysing various neurological substrates of PTSD using functional network models consistently revealed findings in line with previous research on desegregation in PTSD, showing increased connectivity among several networks during rest [44]. The application of Resting state- Functional MRI (rs-fMRI) network models specific to PTSD demonstrates the potential for advancement in the field [44]. The creation of vector-autoregressive networks would enable exploration of time-dependent connections between brain areas in PTSD patients and could be facilitated by temporally accurate techniques such as electroencephalography or magnetoencephalography. DL's ability to combine multimodal data from digital devices like smartphones or smartwatches offers new opportunities for identifying transdiagnostic indicators to remotely detect and monitor individuals at risk. By leveraging advances in computational psychiatry, digital phenotyping can maximise the diagnostic and prognostic value of digitally collected biomarkers. Digital communication also enables the delivery of clinical interventions through telehealth applications. AI and natural language processing are utilised in the evaluation and clinical treatment process [45]. ML techniques have significant potential in developing precise diagnostic and prediction models for PTSD and risk of stress pathology based on a various existing data sources [44].

Artificial Intelligence (AI) in Obsessive Compulsive Disorder (OCD)

Significant advancements have been made in the neurobiology of OCD in recent years [46]. Research in this area has helped in developing neurobiological models of OCD, showcasing international scientific collaboration, and leading to various therapeutic implications. Neuroimaging has been extensively utilised by researchers worldwide to study OCD [46,47]. Early studies indicated the involvement of specific brain circuits and systems in OCD, which is characterised by recurrent intrusive thoughts (obsessions) and compulsive actions [47]. CT, PET, and SPECT have been employed in OCD studies to examine brain morphometry and glucose metabolism [46-49]. Functional Magnetic Resonance Imaging (fMRI) has been used to observe brain activation patterns during specific states related to the condition, incorporating various emotional and cognitive paradigms that may be relevant [47]. For many individuals with OCD, medications and psychological therapies may not be effective [49]. As an alternative therapy, Repetitive Transcranial Magnetic Stimulation (rTMS) has shown promise [46,49]. rTMS and Deep Transcranial Magnetic Stimulation (dTMS) activation affect

different brain targets in OCD, including the supplementary motor area, orbitofrontal cortex/medial prefrontal cortex, dorsolateral prefrontal cortex, and Anterior Cingulate Cortex (ACC) [49]. The introduction of dTMS Hersed (H) coils and functional neuroimaging has advanced focused brain stimulation, bringing us closer to understanding and treating OCD [47]. A study using deep TMS found that increased electroencephalogram activity during attention tasks was associated with an improvement in OCD symptoms, consistent with attention network activation [49].

CONCLUSION(S)

Robotic care and AI-based DL, ML, and DL apps can facilitate the delivery of treatment for mental illnesses, making it more accessible for patients. However, further research is needed to address the significant ethical and societal implications associated with these technologies, and the fields of AI and psychological therapies require continued study. The effectiveness of AI-based therapies in identifying, predicting, and treating mental health issues is remarkably high. AI can provide convenient options for the treatment of mental illnesses, allowing individuals to access care at their own convenience. The integration of AI frameworks can enhance the efficacy and accessibility of existing healthcare systems. To fully realise the potential of AI, collaboration among various stakeholders is essential, including experts in mental healthcare, ethics, technology, engineering, healthcare system management, entrepreneurs, and others. AI plays a crucial role in the early detection, prevention, and intervention of mental health issues. It also contributes to establishing benchmarks for improving individual mental health and providing more accurate and beneficial predictions for personal mental health.

Authors' contribution: MK for conceptualisation, data collection, methodology, original draft and writing review. SA for conceptualisation, supervision and editing. SS for supervision. H for conceptualisation, data curation and editing. AS for editing.

REFERENCES

- [1] Su C, Xu Z, Pathak J, Wang F. Deep learning in mental health outcome research: A scoping review. *Transl Psychiatry*. 2020;10(1):116. Available at: <https://doi.org/10.1038/s41398-020-0780-3>.
- [2] Sajjadi M, Lam RW, Milev R, Rotzinger S, Frey BN, Soares CN, et al. Machine learning in the prediction of depression treatment outcomes: A systematic review and meta-analysis. *Psychological Medicine*. 2021;51(16):2742-51. Available at: <https://doi.org/10.1017/S0033291721003871>.
- [3] Pinaya WH, Mechelli A, Sato JR. Using deep autoencoders to identify abnormal brain structural patterns in neuropsychiatric disorders: A large-scale multi-sample study. *Hum Brain Mapp*. 2019;40(3):944-54. Available at: <https://doi.org/10.1002/hbm.24423>.
- [4] Abd-Alrazaq A, Alajlani M, Alhuwail D, Schneider J, Al-Kuwari S, Shah Z, et al. Artificial intelligence in the fight against COVID-19: Scoping review. *Journal of Medical Internet Research*. 2020;22(12):e20756. Available at: <https://doi.org/10.2196/20756>.
- [5] Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. *Lancet Psychiatry*. 2016;3(2):171-78. Available at: [https://doi.org/10.1016/S2215-0366\(15\)00505-2](https://doi.org/10.1016/S2215-0366(15)00505-2).
- [6] Pedro D. A few useful things to know about machine learning. *Communications of the ACM*. 2012;55(10):78-87. Available at: <https://doi.org/10.1145/2347736.2347755>.
- [7] Zhong X, Shi H, Ming Q, Dong D, Zhang X, Zeng LL, et al. Whole-brain resting-state functional connectivity identified major depressive disorder: A multivariate pattern analysis in two independent samples. *J Affect Disord*. 2017;218:346-52. Available at: <https://doi.org/10.1016/j.jad.2017.04.040>.
- [8] Mehta A, Niles AN, Vargas JH, Marafon T, Couto DD, Gross JJ. Acceptability and effectiveness of artificial intelligence therapy for anxiety and depression (youper): Longitudinal observational study. *J Med Internet Res*. 2021;23(6):e26771. Available at: <https://doi.org/10.2196/26771>.
- [9] Wang X, Ren Y, Zhang W. Depression disorder classification of fMRI data using sparse low-rank functional brain network and graph-based features. *Computational and Mathematical Methods in Medicine*. 2017;2017:e3609821. Available at: <https://doi.org/10.1155/2017/3609821>.
- [10] Schnyer DM, Clasen PC, Gonzalez C, Beevers CG. Evaluating the diagnostic utility of applying a machine learning algorithm to diffusion tensor MRI measures in individuals with major depressive disorder. *Psychiatry Res Neuroimaging*. 2017;264:01-09. Available at: <https://doi.org/10.1016/j.pscychrens.2017.03.003>.

- [11] Bhaumik R, Jenkins LM, Gowins JR, Jacobs RH, Barba A, Bhaumik DK, et al. Multivariate pattern analysis strategies in detection of remitted major depressive disorder using resting state functional connectivity. *Neuroimage Clin*. 2017;16:390-98. Available at: <https://doi.org/10.1016/j.nicl.2016.02.018>.
- [12] Tran T, Luo W, Phung D, Harvey R, Berk M, Kennedy RL, et al. Risk stratification using data from electronic medical records better predicts suicide risks than clinician assessments. *BMC Psychiatry*. 2014;14:76. Available at: <https://doi.org/10.1186/1471-244X-14-76>.
- [13] Garcia-Ceja E, Riegler M, Nordgreen T, Jakobsen P, Oedegaard KJ, Tøresen J. Mental health monitoring with multimodal sensing and machine learning: A survey. *Pervasive and Mobile Computing*. 2018;51:01-26. Available at: <https://doi.org/10.1016/j.pmcj.2018.09.003>.
- [14] Mohr DC, Zhang M, Schueller SM. Personal sensing: Understanding mental health using ubiquitous sensors and machine learning. *Annu Rev Clin Psychol*. 2017;13:23-47. Available at: <https://doi.org/10.1146/annurev-clinpsy-032816-044949>.
- [15] Torous J, Wisniewski H, Bird B, Carpenter E, David G, Elejalde E, et al. Creating a digital health smartphone app and digital phenotyping platform for mental health and diverse healthcare needs: An interdisciplinary and collaborative approach. *J Technol Behav Sci*. 2019;4(2):73-85. Available at: <https://doi.org/10.1007/s41347-019-00095-w>.
- [16] Lee EE, Torous J, De Choudhury M, Depp CA, Graham SA, Kim HC, et al. Artificial intelligence for mental health care: Clinical applications, barriers, facilitators, and artificial wisdom. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2021;6(9):856-64. Available at: <https://doi.org/10.1016/j.bpsc.2021.02.001>.
- [17] Ben-Zeev D, Brian R, Wang R, Wang W, Campbell AT, Aung MSH, et al. Crosscheck: Integrating self-report, behavioral sensing, and smartphone use to identify digital indicators of psychotic relapse. *Psychiatr Rehabil J*. 2017;40(3):266-75. Available at: <https://doi.org/10.1037/prj0000243>.
- [18] Laacke S, Mueller R, Schomerus G, Salloch S. Artificial intelligence, social media and depression: A new concept of health-related digital autonomy. *Am J Bioeth*. 2021;21(7):04-20. Available at: <https://doi.org/10.1080/15265161.2020.1863515>.
- [19] Fulmer R, Joerin A, Gentile B, Lakerink L, Rauws M. Using psychological artificial intelligence (Tess) to relieve symptoms of depression and anxiety: Randomized controlled trial. *JMIR Ment Health*. 2018;5(4):e64. Available at: <https://doi.org/10.2196/mental.9782>.
- [20] Mandar D, Rao V. Depression detection using emotion artificial intelligence. In 2017 International Conference on Intelligent Sustainable Systems (ICISS). 2017;858-62. Available at: <https://doi.org/10.1109/ISSI.2017.8389299>.
- [21] Oliver LD, Hawco C, Viviano JD, Voineskos AN. From the group to the individual in schizophrenia spectrum disorders: Biomarkers of social cognitive impairments and therapeutic translation. *Biological Psychiatry*. 2022;91(8):699-708. Available at: <https://doi.org/10.1016/j.biopsych.2021.09.007>.
- [22] Lai JW, Ang CKE, Acharya UR, Cheong KH. Schizophrenia: A survey of artificial intelligence techniques applied to detection and classification. *Int J Environ Res Public Health*. 2021;18(11):6099. Available at: <https://doi.org/10.3390/ijerph18116099>.
- [23] Koutsouleris N, Kahn RS, Chekroud AM, Leucht S, Falkai P, Wobrock T, et al. Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: A machine learning approach. *Lancet Psychiatry*. 2016;3(10):935-46. Available at: [https://doi.org/10.1016/S2215-0366\(16\)30171-7](https://doi.org/10.1016/S2215-0366(16)30171-7).
- [24] Li A, Zalesky A, Yue W, Howes O, Yan H, Liu Y, et al. A neuroimaging biomarker for striatal dysfunction in schizophrenia. *Nat Med*. 2020;26(4):558-65. Available at: <https://doi.org/10.1038/s41591-020-0793-8>.
- [25] Redlich R, Opel N, Grotegerd D, Dohm K, Zaremba D, Bürger C, et al. Prediction of individual response to electroconvulsive therapy via machine learning on structural magnetic resonance imaging data. *JAMA Psychiatry*. 2016;73(6):557-64. Available at: <https://doi.org/10.1001/jamapsychiatry.2016.0316>.
- [26] Birmaher B, Axelson D, Monk K, Kalas C, Goldstein B, Hickey MB, et al. Lifetime psychiatric disorders in school-aged offspring of parents with bipolar disorder: The Pittsburgh bipolar offspring study. *Arch Gen Psychiatry*. 2009;66(3):287-96. Available at: <https://doi.org/10.1001/archgenpsychiatry.2008.546>.
- [27] Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common genetic risk variants for autism spectrum disorder. *Nature Genetics*. 2019;51(3):431-44. Available at: <https://doi.org/10.1038/s41588-019-0344-8>.
- [28] Wall DP, Kosmicki J, DeLuca TF, Harstad E, Fusaro VA. Use of machine learning to shorten observation-based screening and diagnosis of autism. *Transl Psychiatry*. 2012;2(4):e100-e100. Available at: <https://doi.org/10.1038/tp.2012.10>.
- [29] Duda M, Ma R, Haber N, Wall DP. Use of machine learning for behavioral distinction of autism and ADHD. *Transl Psychiatry*. 2016;6(2):e732-e732. Available at: <https://doi.org/10.1038/tp.2015.221>.
- [30] Bone D, Bishop SL, Black MP, Goodwin MS, Lord C, Narayanan SS. Use of machine learning to improve autism screening and diagnostic instruments: Effectiveness, efficiency, and multi-instrument fusion. *J Child Psychol Psychiatry*. 2016;57(8):927-37. Available at: <https://doi.org/10.1111/jcpp.12559>.
- [31] Marciano F, Venutolo G, Ingenito CM, Verbeni A, Terracciano C, Plunk E, et al. Artificial Intelligence: The "Trait D'Union" in different analysis approaches of autism spectrum disorder studies. *Curr Med Chem*. 2021;28(32):6591-618. Available at: <https://doi.org/10.2174/0929867328666210203205221>.
- [32] Elshoky B, Ibrahim OAS, Ali AA. Machine learning techniques based on feature selection for improving autism disease classification. *International Journal of Intelligent Computing and Information Sciences*. 2021;21(2):65-81. Doi: 10.21608/ijicis.2021.61582.1058.
- [33] Borhani N, Ghaisari J, Abedi M, Kamali M, Ghaisari Y. A deep learning approach to predict inter-omics interactions in multi-layer networks. *BMC Bioinformatics*. 2022;23(1):53. Available at: <https://doi.org/10.1186/s12859-022-04569-2>.

- [34] Eyigoz E, Mathur S, Santamaria M, Cecchi G, Naylor M. Linguistic markers predict onset of Alzheimer's Disease. *EClinicalMedicine*. 2020;28:100583. Available at: <https://doi.org/10.1016/j.eclinm.2020.100583>.
- [35] Fu GS, Levin-Schwartz Y, Lin QH, Zhang D. Machine learning for medical imaging. *Journal of Healthcare Engineering*. 2019;2019:9874591. Available at: <https://doi.org/10.1155/2019/9874591>.
- [36] Suzuki K. Pixel-based machine learning in medical imaging. *International Int J Biomed Imaging*. 2012;2012:e792079. Available at: <https://doi.org/10.1155/2012/792079>.
- [37] Sanfelici R, Dwyer DB, Antonucci LA, Koutsouleris N. Individualized diagnostic and prognostic models for patients with psychosis risk syndromes: A meta-analytic view on the state of the art. *Biological Psychiatry*. 2020;88(4):349-60. Available at: <https://doi.org/10.1016/j.biopsych.2020.02.009>.
- [38] Deping K, He L. Classification on ADHD with Deep Learning. 2014 International Conference on Cloud Computing and Big Data. 2014;27-32. Available at: <https://doi.org/10.1109/CCBD.2014.42>.
- [39] Orrù G, Pettersson-Yeo W, Marquand AF, Sartori G, Mechelli A. Using support vector machine to identify imaging biomarkers of neurological and psychiatric disease: A critical review. *Neurosci Biobehav Rev*. 2012;36(4):1140-52. Available at: <https://doi.org/10.1016/j.neubiorev.2012.01.004>.
- [40] Mayer JS, Hees K, Medda J, Grimm O, Asherson P, Bellina M, et al. Bright light therapy versus physical exercise to prevent co-morbid depression and obesity in adolescents and young adults with attention-deficit/hyperactivity disorder: Study protocol for a randomized controlled trial. *Trials*. 2018;19(1):140. Available at: <https://doi.org/10.1186/s13063-017-2426-1>.
- [41] Koh JEW, Ooi CP, Lim-Ashworth NSJ, Vicnesh J, Tor HT, Lih OS, et al. Automated classification of attention deficit hyperactivity disorder and conduct disorder using entropy features with ECG signals. *Comput Biol Med*. 2022;140:105120. Available at: <https://doi.org/10.1016/j.cplbiomed.2021.105120>.
- [42] Gwernan-Jones R, Moore DA, Cooper P, Russell AE, Richardson M, Rogers M, et al. A systematic review and synthesis of qualitative research: The influence of school context on symptoms of attention deficit hyperactivity disorder. *Emotional and Behavioural Difficulties*. 2016;21(1):83-100. Available at: <https://doi.org/10.1080/13632752.2015.1120055>.
- [43] He Q, Veldkamp BP, Glas CA, de Vries T. Automated assessment of patients' self-narratives for posttraumatic stress disorder screening using natural language processing and text mining. *Assessment*. 2017;24(2):157-72.
- [44] Bourla A, Mouchabac S, El Hage W, Ferreri F. E-PTSD: An overview on how new technologies can improve prediction and assessment of Posttraumatic Stress Disorder (PTSD). *Eur J Psychotraumatol*. 2018;9(sup1):1424448. Available at: <https://doi.org/10.1080/20008198.2018.1424448>.
- [45] Dean KR, Hammamieh R, Mellon SH, Abu-Amara D, Flory JD, Guffanti G, et al. Multi-Omic biomarker identification and validation for diagnosing warzone-related post-traumatic stress disorder. *Molecular Psychiatry*. 2020;25(12):3337-49. Available at: <https://doi.org/10.1038/s41380-019-0496-z>.
- [46] Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, et al. Evidence-based guidelines on the therapeutic use of Repetitive Transcranial Magnetic Stimulation (RTMS): An update (2014–2018). *Clin Neurophysiol*. 2020;131(2):474-528. Available at: <https://doi.org/10.1016/j.clinph.2019.11.002>.
- [47] Harika-Germaneau G, Rachid F, Chatard A, Lafay-Chebassier C, Solinas M, Thirioux B, et al. Continuous theta burst stimulation over the supplementary motor area in refractory obsessive-compulsive disorder treatment: A randomized sham-controlled trial. *Brain Stimul*. 2019;12(6):1565-71. Available at: <https://doi.org/10.1016/j.brs.2019.07.019>.
- [48] Ji GJ, Sun J, Liu P, Wei J, Li D, Wu X, Zhang L, et al. Predicting long-term after-effects of theta-burst stimulation on supplementary motor network through one-session response. *Front Neurosci*. 2020;14:237. Available at: <https://doi.org/10.3389/fnins.2020.00237>.
- [49] Carmi L, Tendler A, Bystritsky A, Hollander E, Blumberger DM, Daskalakis J, et al. Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: A prospective multicenter randomized double-blind placebo-controlled trial. *Am J Psychiatry*. 2019;176(11):931-38. Available at: <https://doi.org/10.1176/appi.ajp.2019.18101180>.

PARTICULARS OF CONTRIBUTORS:

1. MBBS Student, Department of Medicine, Datta Meghe Institute of Medical Sciences, Sawangi (Meghe), Wardha, Maharashtra, India.
2. Professor and Head, Department of Medicine, Datta Meghe Institute of Medical Sciences, Sawangi (Meghe), Wardha, Maharashtra, India.
3. Professor, Department of Pathology, Datta Meghe Institute of Medical Sciences, Sawangi (Meghe), Wardha, Maharashtra, India.
4. MBBS Student, Department of Medicine, Datta Meghe Institute of Medical Sciences, Sawangi (Meghe), Wardha, Maharashtra, India.
5. MBBS Student, Department of Medicine, Datta Meghe Institute of Medical Sciences, Sawangi (Meghe), Wardha, Maharashtra, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Mansi Khare,
Gayatri Hostel, Datta Meghe Institute of Medical Sciences, Sawangi (Meghe),
Wardha-442001, Maharashtra, India.
E-mail: mansikhare40420@gmail.com

PLAGIARISM CHECKING METHODS: [\(Lain H et al.\)](#)

- Plagiarism X-checker: Nov 23, 2022
- Manual Googling: Mar 18, 2023
- iThenticate Software: Oct 27, 2023 (11%)

ETYMOLOGY: Author Origin

EMENDATIONS: 8

AUTHOR DECLARATION:

- Financial or Other Competing Interests: None
- Was Ethics Committee Approval obtained for this study? Yes
- Was informed consent obtained from the subjects involved in the study? Yes
- For any images presented appropriate consent has been obtained from the subjects. NA

Date of Submission: **Nov 21, 2022**

Date of Peer Review: **Mar 11, 2023**

Date of Acceptance: **Jul 10, 2023**

Date of Publishing: **Apr 01, 2024**